– USA, MA – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Michel Lagarde to its Board as an Independent Director.
“We are delighted to have Michel join the Vertex Board. His deep experience across numerous segments of the healthcare industry and markets around the world, as well as his successful track record of growing and scaling profitable businesses, will be valuable as Vertex continues to grow and expand across disease areas, therapeutic modalities, and geographies,” said Executive Chairman, Dr. Jeff Leiden.
About Michel Lagarde
Michel Lagarde is a senior health care and business leader with global expertise, currently serving as COO and EVP of Thermo Fisher Scientific Inc. Before Thermo Fisher, Mr. Lagarde served as President and COO of Patheon, a contract manufacturer to the biopharma industry, and as a MD at JLL Partners, a private equity firm investing in health care services.
“Vertex is at a very exciting time in its history as it builds on its success in cystic fibrosis using its serial innovation strategy,” said Michel Lagarde. “I am honored to join this Board and look forward to working with my fellow directors to help Vertex advance the development and commercialization of many more transformative medicines for the patients who are waiting.”
Before JLL, Mr. Lagarde spent 12 years at Philips, a global leader in health technology, in various finance roles across several international markets. He holds a Bachelor of Business Administration (BBA) degree from European University, Antwerp (Belgium), and an executive master’s degree in finance and control, from Maastricht Universiteit (the Netherlands).
About Vertex Pharmaceuticals
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust clinical pipeline of investigational small molecule, mRNA, cell, and genetic therapies (including gene editing) in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, acute and neuropathic pain, type 1 diabetes and alpha-1 antitrypsin deficiency.
Founded in 1989 in Cambridge, Mass., Vertex’s global headquarters is now located in Boston’s Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, and Latin America. Vertex is consistently recognized as one of the industry’s top places to work, including 13 consecutive years on Science magazine’s Top Employers list and one of Fortune’s 100 Best Companies to Work For.
SOURCE: https://www.vrtx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
